Hepatitis C Patient Management and Family Health Education
NCT ID: NCT03813498
Last Updated: 2019-01-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
1000 participants
INTERVENTIONAL
2019-01-31
2019-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
METHOD: Recruitment will be conduct in 10 hospitals in Jilin, Beijing, Henan and Anhui provinces. The subjects should be patients new diagnosed with hepatitis C at the hospital and aged 18 to 69. After signing the consent form, eligible participants were selected through the inclusion and exclusion criteria. 1000 participants will be recruited for the trial. After completing an baseline reseach by a online questionnaire, patients will be randomly assigned to receive a targeted short article on HCV weekly or a general health article with no mention of HCV. The intervention will last three months and a follow-up will be conduct at three month after the last intervention.
OUTCOMES: The primary outcome is antiviral therapy. The secondary outcomes are cognition and attitude towards hepatitis C, factors influencing antiviral therapy, time to first treatment and the compliance of treatment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Hepatitis C Self-Management
NCT00328042
Motivational Interviewing for HCV Elimination
NCT03804814
Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients
NCT03413696
Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy
NCT01405027
Quality of Life in Patients With HCV Related Liver Cirrhosis Before and After Direct Acting Antiviral Drugs
NCT03897608
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
intervention group
HCV articles
The intervention group receive a targeted short article on HCV from WeChat weekly.
control group
general health articles
The control group receive a general health article with no mention of HCV from WeChat weekly.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HCV articles
The intervention group receive a targeted short article on HCV from WeChat weekly.
general health articles
The control group receive a general health article with no mention of HCV from WeChat weekly.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ages 18-69 (inclusive)
* Both blood anti-HCV test and HCV-RNA test is positive
* Familiar with the use of mobile phones and WeChat
* Informed consent and voluntary participation in the study
Exclusion Criteria
* Suffering from other serious diseases
* Patients with mental disorder or memory disorder
* Pregnant women or those who have a plan to prepare for pregnancy within one year
* Refuse to participate in the investigation
18 Years
69 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Peking University
OTHER
China Liver Health
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Fuqiang Cui, PhD
Role: STUDY_DIRECTOR
Peking University
Tianshuo Zhao
Role: PRINCIPAL_INVESTIGATOR
Study Director
Yingsheng Shen
Role: PRINCIPAL_INVESTIGATOR
China Liver Health
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IN-CN-987-5377
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.